The chief financial officer of the company indicated that it is leaning toward spinning off its orthopedics business rather than selling the unit. Conflict in the Middle East pressured medical-device sales, but the autoimmune and cancer drug Tremfya saw revenue jump 68.3% to $2.4B. CEO Joaquin Duato said the performance reflects momentum toward double-digit growth by 2030, aided by the authorization of the OTTAVA robotic system. Shares of the company fell approximately 2% following the report.
Wednesday, October 21, 2026
Story
Johnson & Johnson Raises 2026 Profit Guide and Signals Orthopedics Spinoff
Earnings8 days ago
Third quarter adjusted earnings for the medical products firm beat estimates at $2.59 per share on sales of $25.4B, which grew 5.9% year over year. Johnson & Johnson increased its full year revenue outlook to a range of $101.0B to $101.4B and raised its adjusted earnings per share forecast to between $11.05 and $11.15. While the company's drug division reported revenue of $16.76B, MedTech sales of $8.64B missed the $8.77B expected by analysts. Reported GAAP earnings per share plummeted 95.8% to $0.09 due to one-time charges for the Firefly Bio acquisition, a Sail Biomedicines collaboration, and a proposed talc litigation settlement.
Looking for more context or analysis?
Tilt chat provides reliable, tailored insights, alerts, and automations.